- Home
- SNOA vs APLM Comparison
SNOA vs APLM Comparison
Compare SNOA & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNOA
- APLM
- Stock Information
- Founded
- SNOA 1999
- APLM 2016
- Country
- SNOA United States
- APLM United States
- Employees
- SNOA N/A
- APLM N/A
- Industry
- SNOA Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- SNOA Health Care
- APLM Finance
- Exchange
- SNOA Nasdaq
- APLM Nasdaq
- Market Cap
- SNOA 6.4M
- APLM 6.9M
- IPO Year
- SNOA 2007
- APLM N/A
- Fundamental
- Price
- SNOA $3.56
- APLM $6.06
- Analyst Decision
- SNOA
- APLM
- Analyst Count
- SNOA 0
- APLM 0
- Target Price
- SNOA N/A
- APLM N/A
- AVG Volume (30 Days)
- SNOA 83.7K
- APLM 28.0K
- Earning Date
- SNOA 08-07-2025
- APLM 08-13-2025
- Dividend Yield
- SNOA N/A
- APLM N/A
- EPS Growth
- SNOA N/A
- APLM N/A
- EPS
- SNOA N/A
- APLM N/A
- Revenue
- SNOA $14,288,000.00
- APLM $198,000.00
- Revenue This Year
- SNOA $23.00
- APLM $415.15
- Revenue Next Year
- SNOA $24.59
- APLM N/A
- P/E Ratio
- SNOA N/A
- APLM N/A
- Revenue Growth
- SNOA 12.20
- APLM N/A
- 52 Week Low
- SNOA $1.75
- APLM $4.47
- 52 Week High
- SNOA $9.00
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- SNOA 59.09
- APLM 48.70
- Support Level
- SNOA $2.97
- APLM $5.11
- Resistance Level
- SNOA $3.75
- APLM $6.56
- Average True Range (ATR)
- SNOA 0.27
- APLM 0.49
- MACD
- SNOA 0.06
- APLM 0.00
- Stochastic Oscillator
- SNOA 55.83
- APLM 63.42
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.